Regeneron reported compelling early results for Lynozyfic, a T cell engager therapy, achieving complete response in all participants in a small study for smoldering multiple myeloma, a precursor to active disease. These findings seek to expand treatment options at earlier disease stages and exemplify growing interest in immuno-oncology approaches beyond traditional relapsed settings, potentially altering disease progression trajectories in hematologic malignancies.